The Role of Cholecalciferol in the Reduction of Insulin Resistance and Rehabilitation of Women with Primary Hypothyreosis

2018 Experimental and Clinical Physiology and Biochemistry  
Introduction. The insufficiency and deficiency of vitamin D is a global health problem. It is known that vitamin D has some immunomodulatory effects in autoimmune thyroid diseases [1] . Numerous non-skeletal diseases associated with vitamin D deficiency have been reported recently, including hypothyroidism [2] . Some studies have shown that vitamin D may play a glucose tolerance through its effects on insulin secretion and sensitivity [3] . In comparison with a healthy control group, patients
more » ... l group, patients with hypothyroidism have a significantly lower circulating concentration of 25(OH)D [4]. Vitamin D reduces insulin resistance probably through its effect on calcium and phosphorus metabolism and through the regulation of the insulin receptor gene [5] . Considering the discordant results, the direct association between the thyroid autoimmunity and newly identified hypothyroidism in the context of type 2 diabetes mellitus [6], and evidence implying a detrimental role of hypothyroidism in insulin sensitivity [7] , it could be stated that the association between insulin resistance and thyroid autoimmunity requires further clarification from both the clinical and research perspectives. In this study our aim is to evaluate the effects of vitamin D supplementation on insulin resistance in women with primary hypothyroidism. Materials and Methods. 72 women, aged 31-75 took part in the study during twelve weeks. Cholecalciferol was added to their medication and the data before and after their supplementation were recorded. During the trial women were instructed not to change the dose of levothyroxine. All participants were checked for thyroid stimulating hormone (TSH) and insulin levels. Serum 25(OH)D was measured by a radioimmunoassay. HOMA-IR (Hemostatic model assessment-Insulin resistance) was calculated. The liver function was assessed by measuring the serum concentration of aspartate aminotransferase and alanine aminotransferase to exclude the liver disease and major non-alcoholic fatty disease of the liver as exclusion criteria that might affect vitamin D metabolism. The main inclusion criteria were absence of hepatic, renal and bone diseases, malignancy, any history of the use of drugs such as anticonvulsants, calcium, vitamin D. The written consent was obtained from all participants. After baseline assessment all patients had been taking 21,000 units of cholecalciferol weekly during 12 weeks. During the treatment, all patients were visited and inter-
doi:10.25040/ecpb2018.04.031 fatcat:2sbxlkt5lfgn7fdxuozoilkhom